LIVE
Apple Launches Health AI Study App for iPhone and Apple Watch Users How to clear app caches on your Mac to free up storage and fix glitches Area Launches Stakuri Plus: A Compact Phone Stand Packed With 17 Cleaning Tools Cloud vs. Local Storage: Which Backup Method Fits Your Gadgets Best? Zelda: Ocarina of Time Remake Review Sparks Metacritic Debate Understanding Sudden Phone Battery Drops: Causes and Fixes What Actually Happens When Your Laptop Battery Drains to Zero Seiko Launches Limited-Edition Touch Chronograph Featuring Unique Baseball-Themed Dial Microsoft Details Project Helix, Emphasizing Console Simplicity Over PC Complexity Apple Continues Refining the iPhone Messages App with New Software Updates Apple Launches Health AI Study App for iPhone and Apple Watch Users How to clear app caches on your Mac to free up storage and fix glitches Area Launches Stakuri Plus: A Compact Phone Stand Packed With 17 Cleaning Tools Cloud vs. Local Storage: Which Backup Method Fits Your Gadgets Best? Zelda: Ocarina of Time Remake Review Sparks Metacritic Debate Understanding Sudden Phone Battery Drops: Causes and Fixes What Actually Happens When Your Laptop Battery Drains to Zero Seiko Launches Limited-Edition Touch Chronograph Featuring Unique Baseball-Themed Dial Microsoft Details Project Helix, Emphasizing Console Simplicity Over PC Complexity Apple Continues Refining the iPhone Messages App with New Software Updates

CDC Study Reveals Widespread Off-Prescription and Compounded GLP-1 Usage Across the US

🧠 AI Analysis 1 min read 👁 1

A new CDC study indicates that roughly 27 million American adults used GLP-1 medications in 2025, with nearly half altering their doses or turning to unapproved compounded alternatives due to cost and availability.

CDC Study Reveals Widespread Off-Prescription and Compounded GLP-1 Usage Across the US🧠AI Analysis

Photo: arstechnica.com

Key points

  • Roughly 27 million US adults used GLP-1 medications in 2025.
  • Nearly half of users modified their dosing due to cost or availability.
  • At least 23 percent of users turned to unapproved compounded alternatives.

Recent findings from the Centers for Disease Control and Prevention indicate that approximately 9.8 percent of US adults—translating to roughly 27 million people—used glucagon-like peptide-1 receptor agonists in 2025 for conditions ranging from diabetes to weight management. However, the data highlights significant gaps between clinical guidelines and real-world application, raising urgent questions regarding patient safety, drug efficacy, and market access.

According to the study, nearly 44 percent of surveyed GLP-1 users admitted to taking the medications differently than prescribed by skipping doses, stretching out refills, or reducing quantities. Over half of those who modified their regimens pointed to financial constraints and supply hurdles, with younger demographics aged 14 to 39 facing the steepest cost barriers at 58 percent, compared to just 20 percent of adults aged 65 and older.

Furthermore, the research underscores a heavy reliance on alternative treatments, with at least 23 percent of users relying on compounded formulations that mimic FDA-approved brand names like Ozempic and Wegovy. Because these compounded variants lack formal FDA evaluation for safety, quality, or effectiveness, the high rate of non-adherence among their users—reaching 62 percent—presents notable public health concerns amplified by misleading online marketing tactics.

Source arstechnica.com — arstechnica.com/health/2026/11/millions-in-us-use-unapproved-glp-1s-and… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.